A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
← catalyst calendarNCT07723963 · readout in 712 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →.
Phase
Phase 2/3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
260estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-01 | estimated | When the study began enrolling |
| Primary completion | 2028-08-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Juvenile Myoclonic Epilepsy
Interventions
- Drug: JZP926 capsule
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in myoclonic seizure days per 28 days (Part A and Part B)
measured Baseline up to end of 16 weeks treatment period
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed